Author of the publication

The multitime case-control design for time-varying exposures.

, , and . Epidemiology (Cambridge, Mass.), 21 (6): 876-83 (November 2010)5909<m:linebreak></m:linebreak>GR: Canadian Institutes of Health Research/Canada; JID: 9009644; ppublish;<m:linebreak></m:linebreak>Dissenys híbrids.
DOI: 10.1097/EDE.0b013e3181f2f8e8

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs., , , , and . Pharmacoepidemiology and drug safety, 16 (8): 845-9 (August 2007)4654<m:linebreak></m:linebreak>LR: 20081121; JID: 9208369; 0 (Central Nervous System Agents); 12794-10-4 (Benzodiazepines); CIN: Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):850-3. PMID: 17636552; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació.Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies., , , , and . Diabetes care, 39 (3): 486-94 (March 2016)Critical appraisal; Bias; Observacionals; Diabetis; Oncologia<br/><br/>Bons gràfics de time bias al material suplementari.ACE-I and ARBs in early diabetic nephropathy., , , , , , , , , and . Journal of the renin-angiotensin-aldosterone system : JRAAS, (xx 12 2002)Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses, , , , , , , , , and 17 other author(s). 329 (16): 1376 (2023)Immortal time bias in observational studies of drug effects.. Pharmacoepidemiology and drug safety, 16 (3): 241-9 (March 2007)4793<m:linebreak></m:linebreak>LR: 20071115; CI: (c) 2007; JID: 9208369; 0 (Adrenergic beta-Agonists); 0 (Gastrointestinal Agents); CIN: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1036. PMID: 18816873; ppublish;<m:linebreak></m:linebreak>Mesures d&#039;associació; Immortal time bias.The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding., , and . European journal of epidemiology, 27 (2): 77-83 (February 2012)6578<m:linebreak></m:linebreak>JID: 8508062; 2011/03/28 received; 2011/11/23 accepted; 2011/12/08 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Marginal structural models.How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias., , , , , and . Pharmacoepidemiology and drug safety, (January 2019)Databases; Anàlisi de dades.Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. Diabetes care, 41 (1): 6-10 (January 2018)Mesures d'associació; Immortal time bias; Diabetis.Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores., , and . Pharmacoepidemiology and drug safety, 26 (4): 459-468 (April 2017)Propensity score; CER; New-user designs; Diabetis.Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals., , , , , , , , , and 38 other author(s). Annals of the American Thoracic Society, 16 (1): 22-28 (January 2019)Causalitat; Confounding; Introductori<br/><br/>Bona Figura i recursos.